The results of this study showed that BPH patients who subsequently developed PRCa have significantly different frequency of harbouring CYP3A4, and VDR at risk genotypes than those BPH patients who did not develop PRCa (13-fold, Tayeb et al, 2002, submitted). The gene discussed is CYP3A4; the disease is pure red-cell aplasia.